Clinical Trials
54 trialsNCT05382559 2026-04-14
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT05516914 2026-04-01
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Completed
NCT05999994 2026-03-27
CAMPFIRE
Eli Lilly and Company
Phase 2 Recruiting
NCT03918278 2025-06-25
MK-0482-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT05673811 2025-04-16
VIRAGE
Theriva Biologics SL
Phase 2 Completed
NCT02723955 2024-12-27
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GlaxoSmithKline
Phase 1 Completed
NCT06696742 2024-11-20
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT02825940 2023-01-04
IMYO29233
Hoffmann-La Roche
Phase 1 Completed
NCT03665441 2022-10-18
Trybeca-1
ERYtech Pharma
Phase 3 Completed
NCT04652206 2021-12-29
PANTAX-Ib
Scandion Oncology A/S
Phase 1/2 Unknown
NCT03669601 2021-06-04
ATRiUM
Cambridge University Hospitals NHS Foundation Trust
Phase 1 Unknown
NCT02559674 2020-01-27
QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel
Altor BioScience
Phase 1 Completed
NCT02071537 2019-11-25
Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors
University of Cincinnati
Phase 1 Completed
NCT01376310 2019-02-19
GSK1120212 Rollover Study
Novartis
Phase 2 Terminated
NCT01764828 2018-11-01
BAY86-9766 Plus Gemcitabine Phase I Study in Asian
Bayer
Phase 1 Completed
NCT01358968 2018-10-25
A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine
Eli Lilly and Company
Phase 1 Completed
NCT02045589 2018-10-01
A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer
Theriva Biologics SL
Phase 1 Completed
NCT02620423 2018-09-13
Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
Oncolytics Biotech
Phase 1 Completed
NCT00954512 2018-08-24
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT02195180 2018-07-27
Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma
ERYtech Pharma
Phase 2 Completed
NCT02241551 2018-07-26
Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
University of Pittsburgh
Phase 2 Terminated
NCT00678132 2018-07-05
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01342224 2018-04-12
Immunochemoradiotherapy in Patients With Pancreatic Cancer
Providence Health & Services
Phase 1 Completed
NCT01285037 2018-02-20
A Study of LY2801653 in Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01460537 2017-10-04
Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer
Bayer
Phase 1 Completed
NCT01016483 2017-07-13
Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer
EMD Serono
Phase 1/2 Completed
NCT01165905 2017-06-23
Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors
Traws Pharma, Inc.
Phase 1 Completed
NCT02723838 2017-03-07
Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder
Oncolytics Biotech
Phase 1 Withdrawn
NCT00811993 2016-11-02
A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Terminated
NCT01447225 2016-09-14
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
Merrimack Pharmaceuticals
Phase 1 Completed
NCT02317419 2016-07-26
A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors
Hoffmann-La Roche
Phase 1 Terminated
NCT00422682 2016-06-10
A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT01251653 2016-05-30
A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel
Boehringer Ingelheim
Completed
NCT01057264 2015-11-18
HAI Abraxane With Gemcitabine and Bevacizumab
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01674556 2015-09-24
Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer
Haukeland University Hospital
Phase 1 Completed
NCT00372437 2015-07-01
A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
Mirati Therapeutics Inc.
Phase 1/2 Completed
NCT01970553 2015-04-01
Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors
PharmaMar
Phase 1 Completed
NCT01455532 2014-10-22
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
Sanofi
Phase 1 Completed
NCT01124786 2014-04-17
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)
Clovis Oncology, Inc.
Phase 2 Completed
NCT00398697 2014-02-13
Phase I Perifosine and Gemcitabine Study
AEterna Zentaris
Phase 1 Completed
NCT01231581 2013-09-26
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
GlaxoSmithKline
Phase 2 Completed
NCT01001221 2013-09-11
Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor
Sanofi
Phase 1/2 Terminated
NCT01830322 2013-08-14
Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer
Cornerstone Pharmaceuticals
Phase 2 Withdrawn
NCT00660426 2013-04-23
Study Of Advanced Gastrointestinal Malignancies And Other Solid Tumors
Washington University School of Medicine
Phase 1 Completed
NCT01713218 2012-10-24
NEOPACHI-001
Erasme University Hospital
Phase EARLY_PHASE1 Unknown
NCT00874042 2012-07-23
Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Completed
NCT01204996 2012-05-30
A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors
Centocor, Inc.
Phase 1 Completed
NCT00454649 2012-04-04
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
Pfizer
Phase 1 Completed
NCT00437203 2012-04-03
PF-00477736 Is Being Studied In Advanced Solid Tumors In Combination With Chemotherapy With Gemcitabine
Pfizer
Phase 1 Terminated
NCT00937664 2011-02-07
Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine
AstraZeneca
Phase 1 Terminated